A number of cancer-specific therapies can cause hypomagnesemia via renal magnesium wasting, including platinum-based chemotherapy, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, inhibitors of human epidermal growth factor receptor 2 (HER2), and calcineurin inhibitors [49]. Here, EGFR is linked to familial primary hypomagnesemia.